CRL4&lt;sup&gt;AMBRA1&lt;/sup&gt;-mediated progesterone receptor degradation drives progestin resistance and represents a therapeutic vulnerability in endometrial cancer. This evidence concerns the gene IL17RB and endometrial cancer.